Larimar Therapeutics, Inc. Common Stock (LRMR)
Larimar Therapeutics, Inc. is a biotechnology company focused on developing treatments for rare and genetically defined diseases. The company utilizes its proprietary drug delivery platform to develop therapies targeting disorders such as Friedreich's ataxia and other neurodegenerative and metabolic conditions. Founded with an emphasis on innovative approaches to challenging diseases, Larimar aims to improve patient outcomes through novel therapeutic solutions.
Company News
DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.
Larimar Therapeutics reported positive results from its ongoing study of nomlabofusp, a potential treatment for Friedreich's Ataxia, showing increased frataxin levels and potential clinical improvements, despite experiencing some anaphylaxis events.
Larimar Therapeutics, a clinical-stage biotech firm, reported Q2 2025 results with a narrower net loss of $0.41 per share. The company continues developing nomlabofusp for Friedreich's ataxia, with ongoing clinical trials and FDA engagement for potential accelerated approval in 2026.
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.